BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 27809600)

  • 1. Plasma hepatocyte growth factor is a novel marker of AL cardiac amyloidosis.
    Swiger KJ; Friedman EA; Brittain EL; Tomasek KA; Huang S; Su YR; Sawyer DB; Lenihan DJ
    Amyloid; 2016 Dec; 23(4):242-248. PubMed ID: 27809600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Matrix metalloproteinases and their tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes and to light chain amyloid deposition.
    Biolo A; Ramamurthy S; Connors LH; O'Hara CJ; Meier-Ewert HK; Soo Hoo PT; Sawyer DB; Seldin DC; Sam F
    Circ Heart Fail; 2008 Nov; 1(4):249-57. PubMed ID: 19808299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of prognostic markers in transthyretin and AL cardiac amyloidosis.
    Damy T; Jaccard A; Guellich A; Lavergne D; Galat A; Deux JF; Hittinger L; Dupuis J; Frenkel V; Rigaud C; Plante-Bordeneuve V; Bodez D; Mohty D
    Amyloid; 2016 Sep; 23(3):194-202. PubMed ID: 27647161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of right ventricular systolic function in cardiac amyloidosis.
    Bodez D; Ternacle J; Guellich A; Galat A; Lim P; Radu C; Guendouz S; Bergoend E; Couetil JP; Hittinger L; Dubois-Randé JL; Plante-Bordeneuve V; Deux JF; Mohty D; Damy T
    Amyloid; 2016 Sep; 23(3):158-167. PubMed ID: 27348696
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of risk assessment in systemic light-chain amyloidosis using human placental growth factor.
    Kristen AV; Rinn J; Hegenbart U; Lindenmaier D; Merkle C; Röcken C; Hardt S; Giannitsis E; Katus HA
    Clin Res Cardiol; 2015 Mar; 104(3):250-7. PubMed ID: 25331161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of cardiac amyloidosis among elderly patients with systolic heart failure or conduction disorders.
    López-Sainz Á; de Haro-Del Moral FJ; Dominguez F; Restrepo-Cordoba A; Amor-Salamanca A; Hernandez-Hernandez A; Ruiz-Guerrero L; Krsnik I; Cobo-Marcos M; Castro V; Toquero-Ramos J; Lara-Pezzi E; Fernandez-Lozano I; Alonso-Pulpon L; González-López E; Garcia-Pavia P
    Amyloid; 2019 Sep; 26(3):156-163. PubMed ID: 31210553
    [No Abstract]   [Full Text] [Related]  

  • 7. Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.
    Longhi S; Quarta CC; Milandri A; Lorenzini M; Gagliardi C; Manuzzi L; Bacchi-Reggiani ML; Leone O; Ferlini A; Russo A; Gallelli I; Rapezzi C
    Amyloid; 2015; 22(3):147-55. PubMed ID: 25997105
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
    Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
    Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The diagnostic challenges of cardiac amyloidosis: A practical approach to the two main types.
    Varga C; Dorbala S; Lousada I; Polydefkis MJ; Wechalekar A; Maurer MS; Comenzo RL
    Blood Rev; 2021 Jan; 45():100720. PubMed ID: 32616304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis.
    Sperry BW; Vranian MN; Hachamovitch R; Joshi H; Ikram A; Phelan D; Hanna M
    J Am Heart Assoc; 2016 Mar; 5(3):e002877. PubMed ID: 27013539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel risk score to predict survival in advanced heart failure due to cardiac amyloidosis.
    Kreusser MM; Volz MJ; Knop B; Ehlermann P; Schmack B; Ruhparwar A; Hegenbart U; Schönland SO; Katus HA; Raake PW
    Clin Res Cardiol; 2020 Jun; 109(6):700-713. PubMed ID: 31630214
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and Evolving Concepts Regarding the Prognosis and Treatment of Cardiac Amyloidosis.
    Perlini S; Mussinelli R; Salinaro F
    Curr Heart Fail Rep; 2016 Dec; 13(6):267-272. PubMed ID: 27900617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Left ventricular structure and function in transthyretin-related versus light-chain cardiac amyloidosis.
    Quarta CC; Solomon SD; Uraizee I; Kruger J; Longhi S; Ferlito M; Gagliardi C; Milandri A; Rapezzi C; Falk RH
    Circulation; 2014 May; 129(18):1840-9. PubMed ID: 24563469
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac transthyretin amyloidosis.
    Dungu JN; Anderson LJ; Whelan CJ; Hawkins PN
    Heart; 2012 Nov; 98(21):1546-54. PubMed ID: 22888163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac amyloidosis in African Americans: comparison of clinical and laboratory features of transthyretin V122I amyloidosis and immunoglobulin light chain amyloidosis.
    Connors LH; Prokaeva T; Lim A; Théberge R; Falk RH; Doros G; Berg A; Costello CE; O'Hara C; Seldin DC; Skinner M
    Am Heart J; 2009 Oct; 158(4):607-14. PubMed ID: 19781421
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The premortem recognition of systemic senile amyloidosis with cardiac involvement.
    Kyle RA; Spittell PC; Gertz MA; Li CY; Edwards WD; Olson LJ; Thibodeau SN
    Am J Med; 1996 Oct; 101(4):395-400. PubMed ID: 8873510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echocardiographic and biohumoral characteristics in patients with AL and TTR amyloidosis at diagnosis.
    Cappelli F; Baldasseroni S; Bergesio F; Perlini S; Salinaro F; Padeletti L; Attanà P; Paoletti Perini A; Moggi Pignone A; Grifoni E; Fabbri A; Marchionni N; Gensini GF; Perfetto F
    Clin Cardiol; 2015 Feb; 38(2):69-75. PubMed ID: 25645201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac amyloidosis without increased left ventricular wall thickness.
    Lee GY; Kim K; Choi JO; Kim SJ; Kim JS; Choe YH; Grogan MA; Jeon ES
    Mayo Clin Proc; 2014 Jun; 89(6):781-9. PubMed ID: 24702732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatocyte growth factor measurement in AL amyloidosis.
    Abraham J; Desport E; Rigaud C; Marin B; Bender S; Lacombe C; Moreau S; Yagoubi F; Bordessoule D; Lavergne D; Bridoux F; Jaccard A
    Amyloid; 2015; 22(2):112-6. PubMed ID: 26053104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.